NeuroMetrix of Boston received CFDA approval to market DPNCheck® in China. DPNCheck is a diagnostic test for diabetic peripheral neuropathy that measures sural nerve conduction velocity in the leg. Although it doesn't measure actual neuropathy, the test has been shown to be a reliable biomarker of the condition. NeuroMetrix has out-licensed China rights for the device to Omron Healthcare, a Japanese medical device company, which managed the China registration process.
